Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 6/20 | 0.55 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.52 |
| ▸ | RORC | P51449 | 2/20 | 0.51 |
| ▸ | FPR3 | P25089 | 3/20 | 0.50 |
| ▸ | HPGDS | O60760 | 1/20 | 0.47 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | JAK1 | P23458 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28943526 | 1.00 | FPR2 (0.55) | FPR2PDE4BRORCFPR3HPGDS | |
| SCHEMBL18557979 | 1.00 | FPR2 (0.55) | FPR2PDE4BRORCFPR3HPGDS | |
| SCHEMBL1015281 | 0.93 | PDE4B (0.58) | FPR2PDE4BRORCFPR3ALDH1A1 | |
| SCHEMBL1015283 | 0.93 | PDE4B (0.58) | FPR2PDE4BRORCFPR3ALDH1A1 | |
| SCHEMBL18509294 | 0.88 | GPR119 (0.54) | PDE4BHPGDSMEN1ALDH1A1MAPT | |
| SCHEMBL20748135 | 0.88 | PDE4B (0.53) | FPR2PDE4BHPGDSMEN1ALDH1A1 | |
| SCHEMBL15187965 | 0.88 | RORC (0.56) | FPR2PDE4BRORCFPR3NAMPT | |
| SCHEMBL1422394 | 0.87 | PDE4B (0.52) | PDE4BHPGDSMEN1ALDH1A1MAPT | |
| SCHEMBL1988650 | 0.87 | PDE4B (0.52) | PDE4BHPGDSMEN1ALDH1A1MAPT | |
| SCHEMBL22810473 | 0.87 | PDE4B (0.52) | PDE4BRORCHPGDSMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115626891-B | Synthesis method of nilaparib key intermediate | 四川轻化工大学 | 2024-01-26 | — | — | CN | claimed |
| CN-115626891-A | Synthesis method of nilapanib key intermediate | 四川轻化工大学 | 2023-01-20 | — | — | CN | claimed |
| EP-4712969-A1 | CYCLIN INHIBITORS | Circle Pharma, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-4709730-A1 | HETEROARYL COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK4 | Celgene Corporation (US) | 2026-03-18 | — | — | EP | disclosed |
| CN-119751337-A | Preparation method of high-purity nilaparib intermediate | 南京唯创远医药科技有限公司 | 2025-04-04 | — | — | CN | disclosed |
| US-20240408169-A1 | CYCLIN INHIBITORS | CIRCLE PHARMA, INC. | 2024-12-12 | — | — | US | disclosed |
| WO-2024233742-A1 | HETEROARYL COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK4 | CELGENE CORPORATION (US) | 2024-11-14 | — | — | WO | disclosed |
| CN-115626891-B | Synthesis method of nilaparib key intermediate | 四川轻化工大学 | 2024-01-26 | — | — | CN | disclosed |
| CN-115626891-B | Synthesis method of nilaparib key intermediate | 四川轻化工大学 | 2024-01-26 | — | — | CN | disclosed |
| CN-114957101-B | Synthesis method of 3-aryl substituted dipiperidone and nilaparil | 山东第一医科大学(山东省医学科学院) | 2023-11-28 | — | — | CN | disclosed |
| CN-113461597-B | Preparation method of nilaparib intermediate | 天津太平洋化学制药有限公司 | 2023-07-21 | — | — | CN | disclosed |
| US-20120245172-A1 | HETEROCYCLIC AMINE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2012-09-27 | — | — | US | disclosed |
| US-20120245172-A1 | HETEROCYCLIC AMINE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2012-09-27 | — | — | US | disclosed |
| WO-2011123419-A1 | TRYCYCLIC COMPOUNDS AND PBK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2011-10-06 | — | — | WO | disclosed |
| EP-2308854-A1 | 2,3,6-trisubstituted-4-pyrimidone derivatives | Sanofi-Aventis (FR) | 2011-04-13 | — | — | EP | disclosed |
| EP-2305651-A1 | 2,3,6-trisubstituted-4-pyrimidone derivatives | Mitsubishi Tanabe Pharma Corporation (JP) | 2011-04-06 | — | — | EP | disclosed |
| US-7504411-B2 | 2,3,6-Trisubstituted-4-pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-03-17 | — | — | US | disclosed |
| US-20060252768-A1 | 2,3,6-Trisubstituted-4-pyrimidone derivatives | SANOFI (FR) | 2006-11-09 | — | — | US | disclosed |
| EP-1608630-A1 | 2, 3, 6-TRISUBSTITUTED-4-PYRIMIDONE DERIVATIVES | Mitsubishi Pharma Corporation (JP) | 2005-12-28 | — | — | EP | disclosed |
| WO-2004085408-A1 | 2, 3, 6-TRISUBSTITUTED-4-PYRIMIDONE DERIVATIVES | MITSUBISHI PHARMA CORPORATION (JP) | 2004-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245172-A1 | HETEROCYCLIC AMINE DERIVATIVES | TAAR1, TAAR5, MTNR1A | FPR2 2048/4885PDE4B 672/4885RORC 524/4885 |
| US-20240408169-A1 | CYCLIN INHIBITORS | CCNI, CDK2, CDK1 | FPR2 4502/4885PDE4B 3643/4885RORC 646/4885 |
| US-20060252768-A1 | 2,3,6-Trisubstituted-4-pyrimidone derivatives | PSEN1, PSEN2, MAPT | FPR2 3254/4885PDE4B 3748/4885RORC 1594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.